Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mina Nikanjam

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2026
Claudin 18.2 Targeting: A Pan-Cancer PerspectiveMina Nikanjam, Judith Pérez-Granado, Mark W Gramling, et al.
Human Movement Science|December 19, 2006
Finger flexor motor control patterns during active flexion: an in vivo tendon force studyMina Nikanjam, Katarzyna Kursa, Steve Lehman, et al.
Cureus|August 9, 2020
Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 TherapyPhilip R Cohen, Mina Nikanjam, Shumei Kato, et al.
Cancer Chemotherapy and Pharmacology|November 24, 2017
Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessmentMina Nikanjam, Edmund V Capparelli, Jeffrey E Lancet, et al.
International Journal of Cancer|September 4, 2019
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patientsMina Nikanjam, David Arguello, Zoran Gatalica, et al.
Oncoimmunology|September 14, 2020
Tumor mutational burden is not predictive of cytotoxic chemotherapy responseMina Nikanjam, Paul Riviere, Aaron Goodman, et al.
Med (New York, N.Y.)|May 15, 2024
Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnessesMina Nikanjam, Kaitlyn Wells, Shumei Kato, et al.
Oncoimmunology|February 1, 2020
Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compoundsDenis L Jardim, Débora De Melo Gagliato, Mina Nikanjam, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 30, 2007
Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiformeMina Nikanjam, Andrew R Gibbs, C Anthony Hunt, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2019
Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patientsSonoko Kawakatsu, Mina Nikanjam, Mark Lin, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2026
Claudin 18.2 Targeting: A Pan-Cancer PerspectiveMina Nikanjam, Judith Pérez-Granado, Mark W Gramling, et al.
Human Movement Science|December 19, 2006
Finger flexor motor control patterns during active flexion: an in vivo tendon force studyMina Nikanjam, Katarzyna Kursa, Steve Lehman, et al.
Cureus|August 9, 2020
Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 TherapyPhilip R Cohen, Mina Nikanjam, Shumei Kato, et al.
Cancer Chemotherapy and Pharmacology|November 24, 2017
Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessmentMina Nikanjam, Edmund V Capparelli, Jeffrey E Lancet, et al.
International Journal of Cancer|September 4, 2019
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patientsMina Nikanjam, David Arguello, Zoran Gatalica, et al.
Oncoimmunology|September 14, 2020
Tumor mutational burden is not predictive of cytotoxic chemotherapy responseMina Nikanjam, Paul Riviere, Aaron Goodman, et al.
Med (New York, N.Y.)|May 15, 2024
Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnessesMina Nikanjam, Kaitlyn Wells, Shumei Kato, et al.
Oncoimmunology|February 1, 2020
Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compoundsDenis L Jardim, Débora De Melo Gagliato, Mina Nikanjam, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 30, 2007
Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiformeMina Nikanjam, Andrew R Gibbs, C Anthony Hunt, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2019
Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patientsSonoko Kawakatsu, Mina Nikanjam, Mark Lin, et al.
Pageof 7